Gout: A Clinical Overview
Gout, a metabolic disorder that affects more than six million people in the United States, most commonly presents as an acute inflammatory arthritis—usually manifesting in an acutely painful, tender, and inflamed joint. Because gout can affect every organ system, however, patients with gout are vulnerable to other significant pathologies that may also require timely intervention.
11. Lawrence RC, Felson DT, Helmick CG, et al; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26-35.
12. CDC. Gout. www.cdc.gov/arthritis/basics/gout.htm. Accessed June 14, 2011.
13. Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29(11):2403-2406.
14. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004; 31(8):1582-1587.
15. Weaver AL. Epidemiology of gout. Cleve Clin J Med. 2008;75 suppl 5:S9-S12.
16. Mandell BF. Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med. 2008;75 suppl 5:S5-S8.
17. Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350(11):1093-1103.
18. Demarco MA, Maynard JW, Huizinga MM, et al. Younger age at gout onset is related to obesity in a community-based cohort. Arthritis Care Res (Hoboken). 2011 Apr 11; [Epub ahead of print].
19. Brook RA, Forsythe A, Smeeding JE, Lawrence Edwards N. Chronic gout: epidemiology, disease progression treatment and disease burden. Curr Med Res Opin. 2010;26(12):2813-2821.
20. Sachs L, Batra KL, Zimmermann B. Medical implications of hyperuricemia. Med Health R I. 2009;92(11):353-355.
21. Kellgren JH, Jeffrey MR, Ball J, eds. The Epidemiology of Chronic Rheumatism: Atlas of Standard Radiographs of Arthritis. Oxford: Blackwell; 1963:327.
22. Wu EQ, Patel PA, Mody RR, et al. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol. 2009;36(5):1032-1040.
23. Riches PL, Wright AF, Ralston SH. Recent insights into the pathogenesis of hyperuricaemia and gout. Hum Mol Genet. 2009;18(R2):R177-R184.
24. Schumacher HR Jr. The pathogenesis of gout. Cleve Clin J Med. 2008;75 suppl 5:S2-S4.
25. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290(3):F625-F631.
26. Zhang W, Doherty M, Pascual E, et al; EULAR (European League Against Rheumatism) Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I: Diagnosis. Ann Rheum Dis. 2006;65(10):1301-1311.
27. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology. 2007;46(8):1372-1374.
28. Eggebeen AT. Gout: an update. Am Fam Physician. 2007;76(6):801-808.
29. Terkeltaub RA. Gout. N Engl J Med. 2003; 349(17):1647-1655.
30. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician. 1999;59(4): 925-934.
31. Schlesinger N. Dietary factors and hyperuricemia. Curr Pharm Des. 2005;11(32):4133-4138.
32. Ning TC, Keenan RT. Unusual presentations of gout. Curr Opin Rheumatol. 2010;22(2): 181-187.
33. Menon RK, Mikhailidis DP, Bell JL, et al. Warfarin administration increases uric acid concentrations in plasma. Clin Chem. 1986;32(8):
1557-1559.
34. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895-900.
35. Martinon F, Glincher LH. Gout: new insights into an old disease. J Clin Invest. 2006;116 (8):2073-2075.
36. Zampogna G, Andracco R, Parodi M, Cimmino MA. Clinical features of gout in a cohort of Italian patients [in Italian]. Reumatismo. 2009; 61(1):41-47.
37. Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol. 2010;22(2):165-172.
38. Bennett PH, Wood PH, eds. Population studies of the rheumatic diseases: proceedings of the Third International Symposium; June 5-10, 1966; New York, NY. Amsterdam: Excerpta Medica Foundation; 1968:457-458.
39. Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol. 2009;15 (1):22-24.
40. Wijnands JMA, Boonen A, Arts ICW, et al. Large epidemiologic studies of gout: challenges in diagnosis and diagnostic criteria. Curr Rheumatol Rep. 2011;13(2):167-174.
41. Dodd LG, Major NM. Fine-needle aspiration cytology of articular and periarticular lesions. Cancer. 2002;96(3):157-165.
42. Dore RK. The gout diagnosis. Cleve Clin J Med. 2008;75 suppl 5:S17-S21.
43. Pettersson T. Sarcoid and erythema nodosum arthropathies. Baillieres Best Pract Res Clin Rheumatol. 2000;14(3):461-476.
44. Córdoba-Fernández A, Rayo-Rosado R. Pseudogout of the first metatarsophalangeal joint associated with hallux valgus: an atypical bilateral case. J Am Podiatr Med Assoc. 2010;100(2):138-142.
45. Dalbeth N, McQueen FM. Use of imaging to evaluate gout and other crystal deposition disorders. Curr Opin Rheumatol. 2009;21(2):124-131.
46. Wu EQ, Forsythe A, Guérin A, et al. Comorbidity burden healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am J Ther. 2011 Feb 10; [Epub ahead of print].
